GlaxoSmithKline reported this week that its combo HIV treatment met its main goal in a study comparing it to a mix of three drugs.
For the study, GSK looked at how well its drug Dovato, which is a mix of dolutegravir and lamivudine, suppressed the HIV virus compared to a trio of drugs containing Gilead’s Vemlidy. Ultimately, GSK said Dovato alone performed as well as the mix of three drugs while limiting patients’ exposure to potentially toxic side effects.
The FDA approved Dovato as the first-ever two-treatment regimen for untreated HIV patients in April. But GSK is looking to continue boosting its prospects in the HIV market over Gilead, the current market leader.
Read the full Reuters report.
